Eye problems in homocystinuria patients, 2018–2022
Part of Brain & nervous system, Eyes & vision, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This study looks at eye problems in people with homocystinuria. It will review medical records from 2018 to 2022 to find out how common eye issues are and what might increase the risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with homocystinuria (by blood test or genetic testing) between 2018 and 2022.
- You can be any age, from newborn to adult.
- You must have had all your medical tests and records completed (no missing information).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study mainly observes what happens in people with homocystinuria caused by a CBS gene deficiency over time. It helps doctors better understand the condition’s natural course and may guide future treatments.
This study uses detailed eye imaging to look for patterns that may go along with conditions like Alzheimer’s disease, memory problems, multiple sclerosis, or eye/vascular issues. It may help researchers better understand how eye findings relate to health and disease.
This study surveys how classical homocystinuria (CBS deficiency) affects daily life and well-being. It includes patients age 8 and up, parents of younger or cognitively impaired children, and medical experts.
This trial tests whether adding a special diet and cysteine supplements can help children with a specific type of homocystinuria grow better and control their lab results. It is for Qatari children who are already following a diet for this condition.
This study looks at a substance in your blood called homocysteine and how it affects the early filling of your heart's main pumping chamber. It may help doctors understand heart risks in people newly diagnosed with high blood pressure.
This trial tests an injectable drug called pegtibatinase for people with a rare condition called homocystinuria. It aims to lower high levels of homocysteine in the blood compared to a placebo, while you continue your usual treatments.
Hear when a new Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.